
Abstract
Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS).
Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309